Dr. Gordon comments on Vulnerable Plaque and Heart Disease
By Linda on Jan 26, 2011 in F.I.G.H.T. | comments(0)
Doctor Gordon’s Comments:
This is vital information; most bypass and stents are operating on the wrong lesions.
Vulnerable plaque is not identifiable at this point, yet is it the only one warranting attention. Most of the stents and bypass surgery are treating lesions that are little or no threat to the patient just like most of the prostate cancers being found would not have contributed to
the patient’s demise. And now we learn that most of the breast lesions discovered on mammograms also warranted nothing more than watch and waiting instead of the rush to surgery and chemo and radiation.
How can you practice advanced medicine and avoid these traps?
I have mentioned a multigated ECG from PREMIER HEART that really identifies significant coronary disease with a simple number. ZERO is what YOU want and that is what my report found. If your report is a SIX, you will in all probability have a significant “event” like a heart attack in less than a year. The equipment costs $35,000 and the test takes 15 minutes and each report costs $50, as you use a supercomputer to review this special advanced ECG.
Read the attached report and look at how bad our competitors are doing who will not learn about IV and oral chelation, Boluoke, Co Q, etc.
Three-year data from 700 patients in prospect announced last fall showed that about 20% of patients with acute coronary syndromes treated with stents and optimal medical therapy have at least one more major adverse cardiac event within three years, but that 12% of these patients’ events were caused by lesions other than the original nonculprit lesion.
I have no reported fatal or non fatal heart attacks when patients are on my total program. Of course, I use that to motivate my patients to really take my heart program seriously!
Of course, if they do then most if not all can overtime improve their score and in time get to the zero if they are willing to do all that I advocate. The same way the $1000 BioClip test shows whose vascular age is inappropriate for their age. You do not want to be 50 years old and have vascular age of a 70 year old person. Again we can routinely reverse that vascular age score or that heart risk score but patients need testing before they will go on any program that costs them money.
Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com
Link: http://www.medscape.com/viewarticle/724138
Excerpt:
From Heartwire
Building Multimodality Pictures to Unlock the Secrets of Vulnerable Plaques
Reed MillerJune 24, 2010 (Hamburg, Germany) — Researchers are developing techniques combining intravascular ultrasound (IVUS) “virtual histology” (VH) with positron-emission tomography (PET) and computed tomography (CT) that they hope will someday predict which coronary plaques trigger MIs.
Dr Martin Bennett (Cambridge University, UK) discussed his group’s research into vulnerable plaque imaging here at the European Atherosclerosis Society (EAS) EAS 2010 Congress. “We know what a vulnerable plaque is–[it is characterized by] a loss of smooth-muscle cells, inflammation, platelet aggregation, expansion of lipid cores. But if we’re trying to detect these features with imaging, we need to focus on particular structural or functional components of those plaques that we can detect using noninvasive imaging techniques.”
IVUS VH, a technology developed by Volcano (San Diego, CA), analyzes ultrasound “backscatter” patterns to differentiate plaque constituents in IVUS coronary images. IVUS VH’s ability to identify fibrous tissue, fibrous fatty tissue, necrotic core, and dense calcification has been validated in postmortem studies with sensitivity and specificity up to 95% to 98%. By assigning different colors to different constituent materials in the vessel wall, IVUS VH can show the thin-cap fibrous atheromas, also known as vulnerable plaques.
Bennett and colleagues studied 200 patients with IVUS VH to see how the coronary substrate wall was different between patients with stable angina and unstable-angina patients. So far, the researchers have processed over 200 m worth of plaque, or about 750 plaques.
